Clinical trial
A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis
NCT02147899 is registered in ClinicalTrials.gov with Symbiomix Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis
- Lead sponsor
- Symbiomix Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- October 31, 2014
- Enrollment
- 215 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
bacterial vaginosis